{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:18:48Z","timestamp":1786382328425,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bioorg.2025.109370","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:16:39Z","timestamp":1765725399000},"page":"109370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["SAR investigation and synergistic optimization of setmelanotide yields a potent, selective, and soluble MC4R agonist"],"prefix":"10.1016","volume":"168","author":[{"given":"Chen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aozhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109370_bb0005","unstructured":"World Obesity Federation. World Obesity Atlas 2025; World Obesity Federation: London, 2025. https:\/\/data.worldobesity.org\/publications\/?cat=23 (accessed 2025-08-30)."},{"key":"10.1016\/j.bioorg.2025.109370_bb0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109370_bb0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with Semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109370_bb0020","first-page":"623","article-title":"The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits","volume":"18","author":"Hinney","year":"2022","journal-title":"Nat. Rev."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109370_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13797","article-title":"Medical semiology of patients with monogenicobesity: a systematic review","volume":"25","author":"Renard","year":"2024","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109370_bb0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41392-022-01149-x","article-title":"Signaling pathways in obesity: mechanisms and therapeutic interventions","volume":"7","author":"Wen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109370_bb0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.molmed.2018.12.002","article-title":"Melanocortin-4 receptor signalling: importance for weight regulation and obesity treatment","volume":"25","author":"K\u00fchnen","year":"2019","journal-title":"T rends Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109370_bb0040","first-page":"E468","article-title":"The melanocortin system","volume":"284","author":"Gantz","year":"2003","journal-title":"Am.J.Physiol.: Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.109370_bb0045","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1021\/acsptsci.4c00129","article-title":"Recommended tool compounds for the melanocortin receptor (MCR) G protein-coupled receptors (GPCRs)","volume":"7","author":"Weirath","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2025.109370_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2010.12.020","article-title":"Structure, function and regulation of the melanocortin receptors","volume":"660","author":"Yang","year":"2011","journal-title":"Eur.J.Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109370_bb0055","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/er.2006-0034","article-title":"Studies on the physiological functions of the melanocortin system","volume":"27","author":"Cone","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2025.109370_bb0060","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.bbadis.2017.03.020","article-title":"Bench-top to clinical therapies: a review of melanocortin ligands from 1954 to 2016","volume":"1863","author":"Ericson","year":"2017","journal-title":"Biochim. Biophys.Acta"},{"key":"10.1016\/j.bioorg.2025.109370_bb0065","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1021\/acs.jmedchem.4c01556","article-title":"N-branched tricyclic Guanidines as novel Melanocortin-3 receptor agonists and Melanocortin-4 receptor antagonists","volume":"68","author":"Weirath","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0070","doi-asserted-by":"crossref","first-page":"T119","DOI":"10.1530\/JME-15-0292","article-title":"60 years of POMC: melanocortin receptors: evolution of ligand selectivity for melanocortin peptides","volume":"56","author":"Dores","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.109370_bb0075","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1021\/acs.jmedchem.2c00793","article-title":"Late-stage functionalization with cysteine Staples generates potent and selective melanocortin Receptor-1 agonists","volume":"65","author":"White","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2018.01.004","article-title":"MC4R agonists: structural overview on Antiobesity therapeutics","volume":"39","author":"Gon\u00e7alves","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.109370_bb0085","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1073\/pnas.77.10.5754","article-title":"4-Norleucine, 7-Dphenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity","volume":"77","author":"Sawyer","year":"1980","journal-title":"Proc. Natl. Acad. Sci.U.S.A."},{"key":"10.1016\/j.bioorg.2025.109370_bb0090","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/jm960840h","article-title":"Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R","volume":"40","author":"Haskell-Luevano","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0095","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1021\/jm049579s","article-title":"Novel 3D pharmacophore of alpha-MSH\/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues","volume":"48","author":"Cai","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0100","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1021\/jm0104872","article-title":"Structure-activity relationships of the melanocortin tetrapeptide ac his-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors. 1. Modifications at the Hisposition","volume":"45","author":"Holder","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0105","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1021\/acs.jmedchem.2c01794","article-title":"\u03a8 and \u03c7 angle constraints at the C-terminus Trp position of the melanotropin tetrapeptide ac-his-D-Phe-Arg-Trp-NH\u2082 Lead to potent and selective agonists at hMC1R and hMC4R","volume":"66","author":"Zhou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41421-023-00586-4","article-title":"Structural insights into ligand recognition and subtype selectivity of the human Melanocortin-3 and Melanocortin-5 receptors","volume":"9","author":"Feng","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.bioorg.2025.109370_bb0115","doi-asserted-by":"crossref","first-page":"21729","DOI":"10.1021\/acs.jmedchem.4c02358","article-title":"Discovery of MT-7117 (Dersimelagon phosphoric acid): a novel, potent, selective, and nonpeptidic orally available melanocortin 1 receptor agonist","volume":"67","author":"Sato","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0120","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acs.jmedchem.9b00053","article-title":"Discovery of Polypharmacological Melanocortin-3 and -4 receptor probes and identification of a 100-fold selective nM MC3R agonist versus a \u03bcM MC4R partial agonist","volume":"62","author":"Fleming","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0125","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1111\/jcmm.17441","article-title":"MC4R biased signalling and the conformational basis of biological function selections","volume":"26","author":"Liu","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109370_bb0130","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.3390\/ijms21165728","article-title":"Structural complexity and plasticity of Signaling regulation at the Melanocortin-4 receptor","volume":"21","author":"Kleinau","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109370_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210389","article-title":"Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism","volume":"14","author":"Minakova","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109370_bb0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1021\/acschemneuro.0c00755","volume":"12","author":"Ericson","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109370_bb0145","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1021\/jm800525p","article-title":"Discovery of orally bioavailable 1,3,4-trisubstituted 2-Oxopiperazine-based Melanocortin-4 receptor agonists as potential Antiobesity agents","volume":"51","author":"Tian","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5114\/ada.2024.138818","article-title":"Afamelanotide in protoporphyria and other skin diseases: a review","volume":"41","author":"Pola\u0144ska","year":"2024","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.bioorg.2025.109370_bb0155","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1060028019899152","article-title":"Bremelanotide: new drug approved for treating hypoactive sexual desire disorder","volume":"54","author":"Mayer","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109370_bb0160","series-title":"US FDA.FDA approves first treatment for weight management for people with certain rare genetic conditions[EB \/OL]","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109370_bb0165","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.aaz8995","article-title":"Determination of the Melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding","volume":"368","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109370_bb0170","unstructured":"Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide in acquired hypothalamic obesity. News release. Rhythm Pharmaceuticals. August 20, 2025. Available from: <https:\/\/www.americanpharmaceuticalreview.com\/1315-News\/620981-FDA-Accepts-sNDA-for-Setmelanotide-in-Acquired-Hypothalamic-Obesity\/>."},{"key":"10.1016\/j.bioorg.2025.109370_bb0175","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of Setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, Phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bioorg.2025.109370_bb0180","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with bardet\u2013biedl syndrome and alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bioorg.2025.109370_bb0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2023.09.015","article-title":"Aqueous remote loading of Setmelanotide in poly(lactic-co-glycolic acid) microspheres for long-term obesity treatment","volume":"364","author":"Wang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2025.109370_bb0190","series-title":"Update on MC4R pathway programs: an R&D event for investors and analysts","volume":"December 6","author":"Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.bioorg.2025.109370_bb0195","series-title":"Methods for treating obesity with an MC4R agonist. WO2024015880A2","author":"Shah","year":"2024"},{"key":"10.1016\/j.bioorg.2025.109370_bb0200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acs.jmedchem.0c01620","article-title":"Structure-based Design of Melanocortin 4 receptor ligands based on the SHU-9119-hMC4R cocrystal structure","volume":"64","author":"Martin","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.109370_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109370_bb0210","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109370_bb0215","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41422-021-00557-y","article-title":"Structural mechanism of calcium-mediated hormone recognition and G beta interaction by the human melanocortin-1 receptor","volume":"31","author":"Ma","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2025.109370_bb0220","series-title":"Structure basis of ligand selectivity and signal transduction in human melanocortin-3 receptor. unpublished results","author":"Jingpeng","year":"2025"},{"key":"10.1016\/j.bioorg.2025.109370_bb0225","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41422-021-00569-8","article-title":"Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-alpha-MSH and setmelanotide","volume":"31","author":"Heyder","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109370_bb0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/79254","article-title":"Inactivation of the mouse Melanocortin-3 receptor results in increased fat mass and reduced lean body mass","volume":"26","author":"Chen","year":"2000","journal-title":"Nat. Genet."},{"issue":"590","key":"10.1016\/j.bioorg.2025.109370_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6434","article-title":"The melanocortin-3 receptor is a pharmacological target for the regulation of anorexia","volume":"13","author":"Sweeney","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109370_bb0240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2005.08.035","article-title":"Divergent functions of central melanocortin pathways in the control of food intake and energy expenditure","volume":"123","author":"Balthasar","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109370_bb0245","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41429-023-00606-1","article-title":"Design, synthesis and antibacterial activity of novel colistin derivatives with thioether bond-mediated cyclic scaffold","volume":"76","author":"Li","year":"2023","journal-title":"J. Antibiotics: Int J."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109370_bb0250","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109370_bb0255","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T20:59:35Z","timestamp":1768942775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S0045206825012507"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109370","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAR investigation and synergistic optimization of setmelanotide yields a potent, selective, and soluble MC4R agonist","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109370"}}